NasdaqGS:ANGO

Stock Analysis Report

Executive Summary

AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally.

Snowflake

Fundamentals

Flawless balance sheet and slightly overvalued.


Similar Companies

Share Price & News

How has AngioDynamics's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0.8%

ANGO

1.9%

US Medical Equipment

0.5%

US Market


1 Year Return

-27.4%

ANGO

15.6%

US Medical Equipment

6.8%

US Market

Return vs Industry: ANGO underperformed the US Medical Equipment industry which returned 15.6% over the past year.

Return vs Market: ANGO underperformed the US Market which returned 6.8% over the past year.


Shareholder returns

ANGOIndustryMarket
7 Day0.8%1.9%0.5%
30 Day-24.0%-2.1%-0.8%
90 Day-31.6%-0.4%-0.9%
1 Year-27.4%-27.4%16.6%15.6%9.2%6.8%
3 Year-13.4%-13.4%72.2%67.0%45.6%36.2%
5 Year-10.2%-10.2%125.9%100.9%63.2%45.4%

Price Volatility Vs. Market

How volatile is AngioDynamics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is AngioDynamics undervalued compared to its fair value and its price relative to the market?

20.3%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: ANGO ($14.63) is trading below our estimate of fair value ($18.35)

Significantly Below Fair Value: ANGO is trading below fair value, but not by a significant amount.


Price To Earnings Ratio

PE vs Industry: ANGO is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.

PE vs Market: ANGO is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ANGO's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ANGO is good value based on its PB Ratio (0.9x) compared to the US Medical Equipment industry average (3.8x).


Next Steps

Future Growth

How is AngioDynamics forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

63.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ANGO is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ANGO is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ANGO is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ANGO's revenue (6.1% per year) is forecast to grow slower than the US market (7.2% per year).

High Growth Revenue: ANGO's revenue (6.1% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ANGO's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has AngioDynamics performed over the past 5 years?

-11.5%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: ANGO is unprofitable, and losses have increased over the past 5 years at a rate of -11.5% per year.

Accelerating Growth: Unable to compare ANGO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ANGO is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (28.2%).


Return on Equity

High ROE: ANGO has a negative Return on Equity (-1.09%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: ANGO is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: ANGO is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is AngioDynamics's financial position?


Financial Position Analysis

Short Term Liabilities: ANGO's short term assets ($166.4M) exceeds its short term liabilities ($47.2M)

Long Term Liabilities: ANGO's short term assets (166.4M) exceeds its long term liabilities (29.1M)


Debt to Equity History and Analysis

Debt Level: ANGO is debt free.

Reducing Debt: ANGO has no debt compared to 5 years ago when its debt to equity ratio was 26.3%.


Balance Sheet

Inventory Level: ANGO has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if ANGO's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable ANGO has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: ANGO is unprofitable but has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by -16.5% per year.


Next Steps

Dividend

What is AngioDynamics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage1.2%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate ANGO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate ANGO's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if ANGO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ANGO's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ANGO's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of AngioDynamics's salary, the management and board of directors tenure and is there insider trading?

3.4yrs

Average management tenure


CEO

Jim Clemmer (55yo)

3.5yrs

Tenure

US$3,001,490

Compensation

Mr. James C. Clemmer, also known as Jim, has been the Chief Executive Officer, President and a Director of AngioDynamics, Inc. since joining it on April 04, 2016. Mr. Clemmer served as Group President of t ...


CEO Compensation Analysis

Compensation vs. Market: Jim's total compensation ($USD3.00M) is about average for companies of similar size in the US market ($USD1.80M).

Compensation vs Earnings: Jim's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

3.4yrs

Average Tenure

51yo

Average Age

Experienced Management: ANGO's management team is considered experienced (3.4 years average tenure).


Board Age and Tenure

5.5yrs

Average Tenure

58yo

Average Age

Experienced Board: ANGO's board of directors are considered experienced (5.5 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

SellUS$41,74708 Nov 18
Michael Greiner
EntityIndividual
Role
Chief Financial Officer
Executive VP & CFO
Shares1,939
Max PriceUS$21.53

Ownership Breakdown


Management Team

  • Warren Nighan (50yo)

    Senior Vice President of Quality & Regulatory Affairs

    • Tenure: 2.5yrs
  • Jim Clemmer (55yo)

    CEO, President & Director

    • Tenure: 3.5yrs
    • Compensation: US$3.00m
  • Stephen Trowbridge (45yo)

    Senior VP

    • Tenure: 9.3yrs
    • Compensation: US$941.40k
  • Michael Greiner (46yo)

    Executive VP & CFO

    • Tenure: 3.2yrs
    • Compensation: US$1.36m
  • Dave Helsel (55yo)

    Senior Vice President of Global Operations and R&D

    • Tenure: 0yrs
    • Compensation: US$958.26k
  • Ben Davis (55yo)

    Senior Vice President of Business Development

    • Tenure: 4.6yrs
  • Chad Campbell (48yo)

    Senior VP & GM of Vascular Access Global Business Unit

    • Tenure: 3.4yrs
    • Compensation: US$1.16m
  • Heather Daniels Cariveau (45yo)

    Senior Vice President of Human Resources

    • Tenure: 3yrs
  • Brent Boucher (52yo)

    Senior VP & GM of Oncology Business

    • Tenure: 0yrs
  • Kim Seabury (52yo)

    Senior Vice President of Information Technology

    • Tenure: 0yrs

Board Members

  • Wesley Johnson (61yo)

    Independent Director

    • Tenure: 12.8yrs
    • Compensation: US$208.01k
  • Howard Donnelly (58yo)

    Independent Non-Executive Chairman

    • Tenure: 5.5yrs
    • Compensation: US$242.01k
  • Eileen Auen (56yo)

    Independent Director

    • Tenure: 3.8yrs
    • Compensation: US$203.19k
  • Frank Veith

    Member of the Scientific Advisory Board

    • Tenure: 0yrs
  • Thomas Sos

    Member of the Scientific Advisory Board

    • Tenure: 0yrs
  • Dennis Meteny (66yo)

    Independent Director

    • Tenure: 15.6yrs
    • Compensation: US$212.01k
  • Stephen Kee

    Member of the Scientific Advisory Board

    • Tenure: 0yrs
  • John Kaufman

    Member of the Scientific Advisory Board

    • Tenure: 0yrs
  • Jacob Cynamon

    Member of the Scientific Advisory Board

    • Tenure: 0yrs
  • Jim Clemmer (55yo)

    CEO, President & Director

    • Tenure: 3.5yrs
    • Compensation: US$3.00m

Company Information

AngioDynamics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: AngioDynamics, Inc.
  • Ticker: ANGO
  • Exchange: NasdaqGS
  • Founded: 1988
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$550.379m
  • Shares outstanding: 37.62m
  • Website: https://www.angiodynamics.com

Number of Employees


Location

  • AngioDynamics, Inc.
  • 14 Plaza Drive
  • Latham
  • New York
  • 12110
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ANGONasdaqGS (Nasdaq Global Select)YesCommon SharesUSUSDMay 2004
UG2DB (Deutsche Boerse AG)YesCommon SharesDEEURMay 2004

Biography

AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgica ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/20 23:51
End of Day Share Price2019/10/18 00:00
Earnings2019/08/31
Annual Earnings2019/05/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.